Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | August 18, 2025 | August 19, 2025 |
| Autolus Therapeutics plcAUTL · Entity 1933 | Director | June 29, 2026 | July 01, 2026 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | June 30, 2021 | July 01, 2021 |
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Director | June 01, 2021 | June 03, 2021 |
| IMMUNIC, INC.IMUX · Entity 6306 | Director | June 29, 2026 | June 29, 2026 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director | June 30, 2021 | July 01, 2021 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | February 28, 2020 | February 29, 2020 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 11, 2019 | June 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date August 18, 2025 · Filed August 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,804 |
Ending reported balance
After 2025-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-18 · Exercise / conversion · Acquired 11,250 · Balance 28,054 F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. Row 2 · 2025-08-18 · Sale · Disposed 11,250 · Balance 16,804 F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.20 · Expires 2026-06-03 | Direct | 0 |
Reported balance
After 2025-08-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-18 · Exercise / conversion · Disposed 11,250 · Balance 0 F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. F3: The stock option was fully vested as of June 3, 2017. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 4,000 |
Reported balance
Holding disclosure · report date 2025-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F2: The shares of ALNY common stock were purchased by the Michael W. Bonney Revocable Trust, of which the reporting person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024.
F2: The shares of ALNY common stock were purchased by the Michael W. Bonney Revocable Trust, of which the reporting person is trustee.
F3: The stock option was fully vested as of June 3, 2017.
Autolus Therapeutics plc
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 31,667 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29 | Direct | 47,500 |
Reported balance
After 2026-06-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
F2: The RSUs vest in one installment on June 29, 2027.
F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.
BRISTOL MYERS SQUIBB CO
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 9,341.7 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 345.331 · Balance 9,341.7 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Dianthus Therapeutics, Inc. /DE/
Report date June 01, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.91 · Expires 2031-05-31 | Direct | 18,188 |
Reported balance
After 2021-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-01 · Grant · Acquired 18,188 · Balance 18,188 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders.
IMMUNIC, INC.
Report date June 29, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.08 · Expires 2036-05-15 | Direct | 100,000 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on May 15, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. F2: The options vest in thirty-six (36) equal installments on each monthly anniversary of May 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on May 15, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.
F2: The options vest in thirty-six (36) equal installments on each monthly anniversary of May 15, 2026.
Kaleido Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2030-06-29 | Direct | 15,000 |
Reported balance
After 2020-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-30 · Grant · Acquired 15,000 · Balance 15,000 F1: The original Form 4, filed on July 1, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the exercise price as $7.42 when in fact the exercise price is 7.43. |
Filing footnotes · ownership attribution and instrument terms
F1: The original Form 4, filed on July 1, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the exercise price as $7.42 when in fact the exercise price is 7.43.
Sarepta Therapeutics, Inc.
Report date February 28, 2020 · Filed February 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,126 |
Reported balance
After 2020-02-28 transaction · row 1
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 2,075 · Balance 9,126 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.47 · Expires 2030-02-28 | Direct | 3,685 |
Reported balance
After 2020-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-28 · Grant · Acquired 3,685 · Balance 3,685 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021.
Syros Pharmaceuticals, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2029-06-10 | Direct | 11,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 11,000 · Balance 11,000 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 2,209 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.78 · Expires 2025-04-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jun 29, 2026 20:30 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $12.08 | $0.00 |
DisclosureSEC source: 0001193805-26-000883 · e665603_4-bonney.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-05-15 F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on May 15, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. F2 · derivative.exercise_date: The options vest in thirty-six (36) equal installments on each monthly anniversary of May 15, 2026. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:04 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantShare Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001730463-26-000091 · form4.xml · derivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: American Depositary Shares · 47,500 shares Expires 2036-06-29 F3 · derivative.exercise_date: Share options vest in twelve equal monthly installments commencing on July 29, 2026. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:04 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantRestricted Share Units · Derivative | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001730463-26-000091 · form4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: American Depositary Shares · 31,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in one installment on June 29, 2027. F2 · derivative.expiration_date: The RSUs vest in one installment on June 29, 2027. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $70.20 | $0.00 |
DisclosureSEC source: 0001735276-25-000087 · edgardoc.xml · derivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2026-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. F3 · derivative.exercise_date: The stock option was fully vested as of June 3, 2017. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 11,250 | $450.00 | $5,062,500.00 |
DisclosureSEC source: 0001735276-25-000087 · edgardoc.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,804 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 11,250 | $70.20 | $789,750.00 |
DisclosureSEC source: 0001735276-25-000087 · edgardoc.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $131.21 | $0.00 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · derivative · entry 17 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F17 · derivative.exercise_date: The stock option was fully vested as of June 1, 2016. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,617 | $283.83 | $458,953.11 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 15 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,804 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $283.54 to $284.22. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,728 | $282.81 | $488,695.68 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 14 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,421 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $282.40 to $283.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 802 | $282.03 | $226,188.06 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 13 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,149 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $281.39 to $282.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 372 | $281.10 | $104,569.20 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 12 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,951 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $280.38 to $281.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 432 | $280.03 | $120,972.96 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 11 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,323 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $279.26 to $280.17. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,239 | $278.01 | $344,454.39 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 10 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,755 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $277.77 to $278.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,263 | $277.16 | $350,053.08 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 9 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,994 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $276.55 to $277.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 301 | $275.63 | $82,964.63 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 8 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,257 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $275.11 to $276.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 882 | $273.75 | $241,447.50 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 7 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,558 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $273.61 to $274.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 660 | $273.16 | $180,285.60 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 6 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,440 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $272.60 to $273.59. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 431 | $271.68 | $117,094.08 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 5 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,100 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $271.44 to $272.10. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 245 | $269.79 | $66,098.55 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,531 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $269.53 to $269.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 729 | $268.56 | $195,780.24 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,776 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $268.28 to $269.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 549 | $267.14 | $146,659.86 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,505 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $266.87 to $267.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 11,250 | $131.21 | $1,476,112.50 |
DisclosureSEC source: 0001735276-25-000072 · edgardoc.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000067 · edgardoc.xml · derivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F3 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000067 · edgardoc.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,804 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-24-000048 · edgardoc.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001735276-23-000081 · edgardoc.xml · derivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2023. F3 · derivative.exercise_date: The stock option was fully vested as of 12/17/2017. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 30,000 | $195.00 | $5,850,000.00 |
DisclosureSEC source: 0001735276-23-000081 · edgardoc.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,029 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2023. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 30,000 | $96.45 | $2,893,500.00 |
DisclosureSEC source: 0001735276-23-000081 · edgardoc.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2023. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 450 | $187.71 | $84,469.50 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 8 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,029 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.58 to $187.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,389 | $187.04 | $259,798.56 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 7 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,479 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.53 to $187.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,714 | $185.99 | $318,786.86 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 6 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,868 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.49 to $186.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,535 | $184.89 | $283,806.15 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 5 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,582 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.48 to $185.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 560 | $183.75 | $102,900.00 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,117 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $183.20 to $184.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 500 | $182.45 | $91,225.00 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,677 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $182.13 to $183.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 300 | $181.08 | $54,324.00 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,177 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $181.00 to $181.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 22,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · derivative · entry 10 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F11 · derivative.exercise_date: The restricted stock units vest in full on the second anniversary of the grant date, August 2, 2021, provided the Reporting Person continues to serve as a director through such anniversary date, or earlier than such anniversary date if he ceases to serve as a director other than for cause or by his voluntary resignation as Executive Chair without the consent of the Board of Directors. F11 · derivative.expiration_date: The restricted stock units vest in full on the second anniversary of the grant date, August 2, 2021, provided the Reporting Person continues to serve as a director through such anniversary date, or earlier than such anniversary date if he ceases to serve as a director other than for cause or by his voluntary resignation as Executive Chair without the consent of the Board of Directors. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 22,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000071 · edgardoc.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $189.87 | $0.00 |
DisclosureSEC source: 0001735276-23-000060 · edgardoc.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 23:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 22,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000075 · edgardoc.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,477 Underlying: Common Stock · 22,477 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of August 2, 2023 and the date the Reporting Person ceases to serve as a director of the Company other than for cause or by his voluntary resignation as Executive Chair without the consent of the Board of Directors. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of August 2, 2023 and the date the Reporting Person ceases to serve as a director of the Company other than for cause or by his voluntary resignation as Executive Chair without the consent of the Board of Directors. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $171.95 | $0.00 |
DisclosureSEC source: 0001735276-21-000069 · edgardoc.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 16:25 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.44 | $0.00 |
DisclosureSEC source: 0001209191-21-044396 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-29 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 21:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 345.331 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000175 · wf-form4_162517420355316.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,341.7 Underlying: Common Stock, $0.10 par value · 345.331 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 13, 2021 Filed Jun 14, 2021 22:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 902 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000150 · wf-form4_162371137972613.xml · derivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 902 shares Expires 2021-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.exercise_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.expiration_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. Read SEC document |
| June 13, 2021 Filed Jun 14, 2021 22:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 902 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000150 · wf-form4_162371137972613.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 2,949 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000146 · wf-form4_162283897591681.xml · derivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,949 Underlying: Common Stock, $0.10 par value · 2,949 shares Expires 2022-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.exercise_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.expiration_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,949 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-21-000146 · wf-form4_162283897591681.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:33 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0000899243-21-021843 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 17:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 365.516 | $63.13 | $23,075.03 |
DisclosureSEC source: 0000014272-21-000120 · wf-form4_161738398243865.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,930.258 Underlying: Common Stock, $0.10 par value · 365.516 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:15 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,054.171 | $62.21 | $189,999.98 |
DisclosureSEC source: 0000014272-21-000044 · wf-form4_161239771027164.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,564.742 Underlying: Common Stock, $0.10 par value · 3,054.171 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 371.997 | $62.03 | $23,074.97 |
DisclosureSEC source: 0000014272-21-000018 · wf-form4_160989540756255.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,467.507 Underlying: Common Stock, $0.10 par value · 371.997 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.